Article Sidebar
Published:
Feb 7, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Identification of the anti-COVID-19 mechanism of action of Han-Shi Blocking Lung using network pharmacology-integrated molecular docking
Abstract
Purpose: To investigate the bio-active components and the potential mechanism of the prescription remedy, Han-Shi blocking lung, with network pharmacology with a view to expanding its application.
Methods: Chemical components were first collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Pharmmapper database and GeneCards were used to predict the targets related to active components and COVID-19. Using DAVIDE and KOBAS 3.0 databases, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were enriched. A “components-targets-pathways” (C-T-P) network was conducted by Cytoscape 3.7.1 software. With the aid of Discovery Studio 2016 software, bio-active components were selected to dock with SARS-COV-2 3CL and ACE2.
Results: From the prescription, 47 bio-active components, 83 targets and 103 signaling pathways were obtained in total (p < 0.05). 126 GO entries (p < 0.05) were screened by GO enrichment analysis. Molecular docking results showed that procyanidin B1 eriodictyol, (4E, 6E)-1, 7-bis(4- hydroxyphenyl)hepta-4, 6-dien-3-one, and quercetin had higher docking scores with SARS-COV-2 3CL and ACE2.
Conclusion: With network pharmacology and molecular docking, the bio-active components and targets of this prescription, Han-Shi blocking lung, against COVID-19 were identified. Taken together, this study provided a basis for the treatment of COVID-19 and further promotion of this prescription.
